Skip to main content
SpringerLink
Log in

High Throughput Screening for Stabilizers of Vaccine Antigens

  • Chapter
  • First Online:
Book cover Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

  • 1234 Accesses

Abstract

The formulation and stabilization of vaccines remains one of the most problematic steps in their development [1, 2]. Once an antigen has been identified, its conversion into an efficacious, safe, convenient, and stable dosage form that can be effectively delivered to a target population is often beset with numerous difficulties. Not the least of these is the many different types of vaccine antigens, each with its own individual chemical identity, the presence of associated multiple physical characteristics and degradation pathways as well as accompanying delivery problems. Types of vaccine antigens in rough order of their complexity include peptides, peptide conjugates, natural and recombinant proteins, DNA-based systems, carbohydrate and carbohydrate-conjugates, virus-like particles, live-attenuated and inactivated viruses and bacteria among others. Thus biological macromolecules such as proteins, nucleic acids, polysaccharides, and lipids all may play roles as key components in vaccines and require appropriate attention. Furthermore, many vaccine formulations include an adjuvant which itself can be quite complex in nature (e.g., aluminum salts and oil-in-water emulsions) as well as in terms of adjuvant interactions with antigens and other solution components.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hem SL, HogenEsch H, Middaugh CR, Volkin DB (2010) Preformulation studies—the next advance in aluminum adjuvant-containing vaccines. Vaccine 28:4868–4870

    Article  PubMed  CAS  Google Scholar 

  2. Volkin DB, Middaugh CR (2010) Vaccines as physically and chemically well-defined pharmaceutical dosage forms. Expert Rev Vaccines 9(7):689–691

    Article  PubMed  CAS  Google Scholar 

  3. Singh M (2007) Vaccine adjuvants and delivery systems. Wiley & Sons Inc., Hoboken, New Jersey

    Google Scholar 

  4. Ausar SF, Chan J, Hoque W, James O, Jayasundara K, Harper K (2011) Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. J Pharm Sci 100:431–440

    Article  PubMed  CAS  Google Scholar 

  5. Middaugh CR, Siahaan T (2011) Pharmaceutical biotechnology. In: In: Sinko PJ (ed) Martin’s physical pharmacy and pharmaceutical sciences. Wolters Kluner & Lippincott Williams and Wilkins, pp 516–562, Baltimore, MD

    Google Scholar 

  6. Jiscoot M, Crommelin D (2005) Methods for structural analysis of protein pharmaceuticals. AAPS Press, Arlington

    Google Scholar 

  7. Joshi S, Bhambhani A, Zeng Y, Middaugh CR (2010) An empirical phase diagram/high throughput screening approach to the characterization and formulation of biopharmaceuticals. In: Jameel F and Hershenson S (ed) Formulation and process development strategies for manufacturing biopharmaceuticals. Wiley, pp 173–204, Hoboken, New Jersey

    Google Scholar 

  8. Hawe A, Sutter M, Jiskoot W (2008) Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25:1487–1499

    Article  PubMed  CAS  Google Scholar 

  9. Philo JS (2009) A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10:359–372

    Article  PubMed  CAS  Google Scholar 

  10. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D (2009) A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10:373–381

    Article  PubMed  CAS  Google Scholar 

  11. Wuchner K, Buchler J, Spycher R, Dalmonte P, Volkin DB (2010) Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 99:3343–3361

    Article  PubMed  CAS  Google Scholar 

  12. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB (2010) Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99:2582–2597

    PubMed  CAS  Google Scholar 

  13. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B (2009) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98:1201–1205

    Article  PubMed  CAS  Google Scholar 

  14. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G (2010) Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 99:2200–2208

    Article  PubMed  CAS  Google Scholar 

  15. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR (2011) Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100:4171–4197

    Google Scholar 

  16. Zeng Y, Fan H, Chiueh G, Pham B, Martin R, Lechuga-Ballesteros D, Truong VL, Joshi SB, Middaugh CR (2009) Towards development of stable formulations of a live attenuated bacterial vaccine: a preformulation study facilitated by a biophysical approach. Hum Vaccin 5:322–331

    Article  PubMed  CAS  Google Scholar 

  17. Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR (2006) A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 24:5839–5851

    Article  PubMed  CAS  Google Scholar 

  18. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang CR, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ (2006) Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 95:80–96

    Article  PubMed  CAS  Google Scholar 

  19. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR (2008) Physical characterization of clostridium difficile toxins and toxoids: effect of the formaldehyde crosslinking on thermal stability. J Pharm Sci 97:3735–3752

    Article  PubMed  CAS  Google Scholar 

  20. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR (2008) Preformulation studies of Clostridium difficile toxoids A and B. J Pharm Sci 97:4194–4207

    Google Scholar 

  21. Barrett BS, Picking WL, Picking WD, Middaugh CR (2008) The response of type three secretion system needle proteins MxiHDelta5, BsaLDelta5, and PrgIDelta5 to temperature and pH. Proteins Struct Funct Bioinforma 73:632–643

    Article  CAS  Google Scholar 

  22. Markham A, Birket S, Picking WD, Picking WL, Middaugh CR (2007) pH sensitivity of type III secretion system tip proteins. Proteins Struct Funct Bioinforma 71:1830–1842

    Article  Google Scholar 

  23. Barrett BS, Markham AP, Esfandiary R, Picking WL, Picking WD, Joshi SB, Middaugh CR (2010) Formulation and immunogenicity studies of type III secretion system needle antigens as vaccine candidates. J Pharm Sci 99:4488–4496

    Article  PubMed  CAS  Google Scholar 

  24. Markham AP, Barrett BS, Esfandiary R, Picking WL, Picking WD, Joshi SB, Middaugh CR (2010) Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine. J Pharm Sci 99:4497–4509

    Article  PubMed  CAS  Google Scholar 

  25. Cai S, He F, Samra HS, de la Maza LM, Bottazzi ME, Joshi SB, Middaugh CR (2009) Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Mol Pharm 6:1553–1561

    Article  PubMed  CAS  Google Scholar 

  26. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR (2006) Conformational stability and disassembly of Norwalk virus like particles: effect of pH and temperature. J Biol Chem 281:19478–19488

    Article  PubMed  CAS  Google Scholar 

  27. Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedvick TS, Middaugh CR (2008) Physical stabilization of Norwalk virus-like particles. J Pharm Sci 97:4208–4218

    Article  PubMed  CAS  Google Scholar 

  28. Kissmann J, Joshi SB, Haynes JR, Dokken L, Richardson C, Middaugh CR (2011) H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers. J Pharm Sci 100:634–645

    Article  PubMed  CAS  Google Scholar 

  29. He F, Joshi SB, Bosman F, Verhaeghe M, Middaugh CR (2009) Structural stability of hepatitis C virus envelope glycoprotein E1: effect of pH and dissociative detergents. J Pharm Sci 98:3340–3357

    Article  PubMed  CAS  Google Scholar 

  30. Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, Federspiel MJ, Joshi SB, Middaugh CR (2008) Stabilization of measles virus for vaccine formulation. Hum Vaccin 4:350–359

    Article  PubMed  Google Scholar 

  31. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR (2005) Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2:491–499

    Article  PubMed  CAS  Google Scholar 

  32. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, Middaugh CR (2007) High-through put screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin 3:94–103

    Article  PubMed  CAS  Google Scholar 

  33. Esfandiary R, Yee L, Ohtake S, Martin RA, Truong-Le VL, Lechuga-Ballesteros D, Moore DS, Joshi SB, Middaugh CR (2010) Biophysical characterization of rotavirus serotypes G1, G3 and G4. Hum Vaccin 6:390–398

    Article  PubMed  CAS  Google Scholar 

  34. He F, Joshi SB, Moore DS, Shinogle HE, Ohtake S, Lechuga-Ballesteros D, Martin RA, Truong-Le VL, Middaugh CR (2010) Using spectroscopic and microscopic methods to probe the structural stability of human adenovirus type 4. Hum Vaccin 6:202–211

    Article  PubMed  Google Scholar 

  35. Rexroad J, Martin TT, McNeilly D, Godwin S, Middaugh CR (2006) Thermal stability of Adenovirus type 2 as a function of pH. J Pharm Sci 95:1469–1479

    Article  PubMed  CAS  Google Scholar 

  36. Rexroad J, Evans RK, Middaugh CR (2006) Effect of pH and ionic strength on the physical stability of adenovirus type 5. J Pharm Sci 95:237–247

    Article  PubMed  CAS  Google Scholar 

  37. Rexroad J, Wiethoff CM, Green AP, Kierstead TD, Scott MO, Middaugh CR (2003) Structural stability of adenovirus type 5. J Pharm Sci 92:665–678

    Article  PubMed  CAS  Google Scholar 

  38. Middaugh CR, Evans RK, Montgomery DL, Casimiro DR (1998) Analysis of plasmid DNA from a pharmaceutical perspective. J Pharm Sci 87:130–146

    Article  PubMed  CAS  Google Scholar 

  39. Middaugh CR, Ramsey JD (2007) Analysis of cationic-lipid-plasmid-DNA complexes. Anal Chem 79:7240–7248

    Article  PubMed  Google Scholar 

  40. Ausar SF, Joshi SB, Middaugh CR (2008) Spectroscopic methods for the physical characterization and formulation of nonviral gene delivery systems. Methods Mol Biol 434:55–80

    PubMed  CAS  Google Scholar 

  41. Ruponen M, Braun CS, Middaugh CR (2006) Biophysical characterization of polymeric and liposomal gene delivery systems using empirical phase diagrams. J Pharm Sci 95:2101–2114

    Article  PubMed  CAS  Google Scholar 

  42. Evans RK, Xu Z, Bohannon KE, Wang B, Bruner MW, Volkin DB (2000) Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. J Pharm Sci 89:76–87

    Article  PubMed  CAS  Google Scholar 

  43. Zeng Y, Ramsey JD, King R, Leviten M, McGuire R, Volkin DB, Joshi SB, Middaugh CR (2011) Identifying stabilizers of plasmid DNA for pharmaceutical use. J Pharm Sci 100:904–914

    Article  PubMed  CAS  Google Scholar 

  44. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI (2010) High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99:1707–1720

    PubMed  CAS  Google Scholar 

  45. Li Y, Mach H, Blue JT (2011) High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J Pharm Sci 100:2120–2135

    Article  PubMed  CAS  Google Scholar 

  46. He F, Phan DH, Hogan S, Bailey R, Becker GW, Narhi LO, Razinkov VI (2010) Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci 99:2598–2608

    PubMed  CAS  Google Scholar 

  47. Mach H, Bhambhani A, Meyer BK, Burek S, Davis H, Blue JT, Evans RK (2011) The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. J Pharm Sci 100:1671–1678

    Article  PubMed  CAS  Google Scholar 

  48. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI (2010) High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 399:141–143

    Article  PubMed  CAS  Google Scholar 

  49. He F, Woods CE, Litowski JR, Roschen LA, Gadgil HS, Razinkov VI, Kerwin BA (2011) Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm Res 28:1552–1560

    Article  PubMed  CAS  Google Scholar 

  50. He F, Woods CE, Trilisky E, Bower KM, Litowski JR, Kerwin BA, Becker GW, Narhi LO, Razinkov VI (2011) Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J Pharm Sci 100:1330–1340

    Article  CAS  Google Scholar 

  51. Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, Alvarez JC, Volkin DB (2011) Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J Pharm Sci 100:1009–1021

    Article  PubMed  CAS  Google Scholar 

  52. Zhao H, Graf O, Milovic N, Luan X, Bluemel M, Smolny M, Forrer K (2010) Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 99:2279–2294

    PubMed  CAS  Google Scholar 

  53. Li N, Kessler K, Bass L, Zeng D (2007) Evaluation of the iCE280 Analyzer as a potential high-throughput tool for formulation development. J Pharm Biomed Anal 43:963–972

    Article  PubMed  CAS  Google Scholar 

  54. Szabo Z, Guttman A, Bones J, Karger BL (2011) Rapid high-resolution characterization of functionally important monoclonal antibody N-glycans by capillary electrophoresis. Anal Chem 83:5329–5336

    Article  PubMed  CAS  Google Scholar 

  55. Lao WI, Wang YF, Kuo YD, Lin CH, Chang TC, Su IJ, Wang JR, Chang CF (2011) Profiling of influenza viruses by high-throughput carbohydrate membrane array. Future Med Chem 3:283–296

    Article  PubMed  CAS  Google Scholar 

  56. King AC, Woods M, Liu W, Lu Z, Gill D, Krebs MR (2011) High throughput measurement, correlation analysis and machine learning predictions for pH and thermal stabilities of Pfizer-generated antibodies. Protein Sci 20(9):1546–1557

    Google Scholar 

  57. Kamerzell TJ, Middaugh CR (2008) The complex inter-relationships between protein flexibility and stability. J Pharm Sci 97:3494–3517

    Article  PubMed  CAS  Google Scholar 

  58. Ramsey JD, Gill ML, Kamerzell TJ, Price ES, Joshi SB, Bishop SM, Oliver CN, Middaugh CR (2009) Using empirical phase diagrams to understand the role of intramolecular dynamics in immunoglobulin G stability. J Pharm Sci 98:2432–2447

    Google Scholar 

  59. Kamerzell TJ, Ramsey JD, Middaugh CR (2008) Immunoglobulin dynamics, conformational fluctuations, and nonlinear elasticity and their effects on stability. J Phys Chem 112:3240–3250

    Article  CAS  Google Scholar 

  60. Kamerzell TJ, Middaugh CR (2007) Two-dimensional correlation spectroscopy reveals coupled immunoglobulin regions of differential flexibility that influence stability. Biochemistry 46:9762–9773

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, KU School of Pharmacy, Kansas University, Lawrence, KS, USA

    C. Russell Middaugh, David B. Volkin & Sangeeta B. Joshi

Authors
  1. C. Russell Middaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David B. Volkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sangeeta B. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Russell Middaugh .

Editor information

Editors and Affiliations

  1. Novartis Vaccines Research, Cambridge, 02139, Massachusetts, USA

    Manmohan Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Middaugh, C.R., Volkin, D.B., Joshi, S.B. (2013). High Throughput Screening for Stabilizers of Vaccine Antigens. In: Singh, M. (eds) Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-5380-2_6

Download citation

Publish with us

Policies and ethics

Search

Navigation